The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation
Open accessAbstract
For differentiation-defective malignancies, compounds that modulate transcription, such as retinoic acid and histone deacetylase (HDAC) inhibitors, are of particular interest. HDAC inhibitors are currently under investigation for the treatment of a broad spectrum of cancer diseases. However, one clinical drawback is class-specific toxicity of unselective inhibitors, limiting their full anticancer potential. Selective targeting of individual HDAC isozymes in defined tumor entities may therefore be an attractive alternative treatment approach. We have previously identified HDAC family member 8 (HDAC8) as a novel target in childhood neuroblastoma. Using small-molecule inhibitors, we now demonstrate that selective inhibition of HDAC8 exhibits antineuroblastoma activity without toxicity in two xenograft mouse models of MYCN oncogene-amplified neuroblastoma. In contrast, the unselective HDAC inhibitor vorinostat was more toxic in the same models. HDAC8-selective inhibition induced cell cycle arrest and differentiation in vitro and in vivo. Upon combination with retinoic acid, differentiation was significantly enhanced, as demonstrated by elongated neurofilament-positive neurites and upregulation of NTRK1. Additionally, MYCN oncogene expression was downregulated in vitro and tumor cell growth was markedly reduced in vivo. Mechanistic studies suggest that cAMP-response element-binding protein (CREB) links HDAC8- and retinoic acid-mediated gene transcription. In conclusion, HDAC-selective targeting can be effective in tumors exhibiting HDAC isozyme-dependent tumor growth in vivo and can be combined with differentiation-inducing agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584
HDAC family: What are the cancer relevant targets?
Witt, O., Deubzer, H. E., Milde, T., & Oehme, I. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.016 · Cited by 1,069
Self-citationChemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710
HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle
Deardorff, M. A., Bando, M., Nakato, R., Watrin, E., Itoh, T., Minamino, M., Saitoh, K., Komata, M., Katou, Y., Clark, D., et al. (2012) · Nature · doi:10.1038/nature11316 · Cited by 577
Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458
Histone deacetylase 8 in neuroblastoma tumorigenesis
Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0684 · Cited by 398
Self-citation
Research works printed but not linked: 36
- Brodeur GM . Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203–216. · DOI · Paper page
- Van Roy N, De Preter K, Hoebeeck J, Van Maerken T, Pattyn F, Mestdagh P et al. The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Med 2009; 1: 74. · DOI
- Witt O, Deubzer HE, Lodrini M, Milde T, Oehme I . Targeting histone deacetylases in neuroblastoma. Curr Pharm Des 2009; 15: 436–447. · DOI
- Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23: 3923–3931. · DOI · Paper page
- Lane AA, Chabner BA . Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 5459–5468. · DOI · Paper page
- Balasubramanian S, Verner E, Buggy JJ . Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 2009; 280: 211–221. · DOI · Paper page
- Krennhrubec K, Marshall BL, Hedglin M, Verdin E, Ulrich SM . Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett 2007; 17: 2874–2878. · DOI · Paper page
- Molenaar JJ, Koster J, Ebus ME, van Sluis P, Westerhout EM, de Preter K et al. Copy number defects of G1-cell cycle genes in neuroblastoma are frequent and correlate with high expression of E2F target genes and a poor prognosis. Genes Chromosomes Cancer 2012; 51: 10–19. · DOI
- Ng HH, Bird A . Histone deacetylases: silencers for hire. Trends Biochem Sci 2000; 25: 121–126. · DOI
- Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 2007; 104: 8071–8076. · DOI · Paper page
- Thiele CJ, Reynolds CP, Israel MA . Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985; 313: 404–406. · DOI · Paper page
- Armstrong JL, Redfern CP, Veal GJ . 13-Cis retinoic acid and isomerisation in paediatric oncology – is changing shape the key to success? Biochem Pharmacol 69: 1299–1306. · DOI
- Jiang M, Zhu K, Grenet J, Lahti JM . Retinoic acid induces caspase-8 transcription via phospho-CREB and increases apoptotic responses to death stimuli in neuroblastoma cells. Biochim Biophys Acta 2008; 1783: 1055–1067. · DOI
- Gao J, Siddoway B, Huang Q, Xia H . Inactivation of CREB mediated gene transcription by HDAC8 bound protein phosphatase. Biochem Biophys Res Commun 2009; 379: 1–5. · DOI
- Ghee M, Baker H, Miller JC, Ziff EB . AP-1, CREB and CBP transcription factors differentially regulate the tyrosine hydroxylase gene. Brain Res Mol Brain Res 1998; 55: 101–114. · DOI
- Matthay KK, George RE, Yu AL . Promising therapeutic targets in neuroblastoma. Clin Cancer Res 2012; 18: 2740–2753. · DOI · Paper page
- Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013; 45: 279–284. · DOI · Paper page
- Minucci S, Pelicci PG . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38–51. · DOI · Paper page
- Yoo CB, Jones PA . Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006; 5: 37–50. · DOI · Paper page
- Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002; 21: 2672–2681. · DOI · Paper page
- Montgomery RL, Potthoff MJ, Haberland M, Qi X, Matsuzaki S, Humphries KM et al. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 2008; 118: 3588–3597. · DOI · Paper page
- Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 2007; 13: 324–331. · DOI · Paper page
- Waltregny D, De Leval L, Glénisson W, Ly Tran S, North BJ, Bellahcène A et al. Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. Am J Pathol 2004; 165: 553–564. · DOI
- Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ et al. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst 2007; 99: 1107–1119. · DOI
- Lodrini M, Oehme I, Schroeder C, Milde T, Schier MC, Kopp-Schneider A et al. MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res 2013; 41: 6018–6033. · DOI
- Fabian J, Lodrini M, Oehme I, Schier MC, Thole TM, Hielscher T et al. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. Cancer Res 2014; 74: 2604–2616. · DOI
- Haberland M, Mokalled MH, Montgomery RL, Olson EN . Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev 2009; 23: 1625–1630. · DOI · Paper page
- Higuchi T, Nakayama T, Arao T, Nishio K, Yoshie O . SOX4 is a direct target gene of FRA-2 and induces expression of HDAC8 in adult T-cell leukemia/lymphoma. Blood 2013; 121: 3640–3649. · DOI
- Schilham MW, Oosterwegel MA, Moerer P, Ya J, de Boer PA, van de Wetering M et al. Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4. Nature 1996; 380: 711–714. · DOI · Paper page
- Potzner MR, Tsarovina K, Binder E, Penzo-Méndez A, Lefebvre V, Rohrer H et al. Sequential requirement of Sox4 and Sox11 during development of the sympathetic nervous system. Development 2010; 137: 775–784. · DOI
- Bergsland M, Werme M, Malewicz M, Perlmann T, Muhr J . The establishment of neuronal properties is controlled by Sox4 and Sox11. Genes Dev 2006; 20: 3475–3486. · DOI · Paper page
- Olson DE, Udeshi ND, Wolfson NA, Pitcairn CA, Sullivan ED, Jaffe JD et al. An unbiased approach to identify endogenous substrates of "histone" deacetylase 8. ACS Chem Biol 2014; 17: 2210–6. · DOI
- Chu PW, Cheung WM, Kwong YL . Differential effects of 9-cis, 13-cis and all-trans retinoic acids on the neuronal differentiation of human neuroblastoma cells. Neuroreport 2003; 14: 1935–1939. · doi:10.1097/00001756-200310270-00011
- Fulda S, Debatin KM . 5-Aza-2'-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene 2006; 25: 5125–5133. · DOI
- Milde T, Oehme I, Korshunov A, Kopp-Schneider A, Remke M, Northcott P et al. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin Cancer Res 2010; 16: 3240–3252. · DOI · Paper page
- Fischer M, Skowron M, Berthold F . Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. J Mol Diagn 7: 89–96. · DOI
Cited by
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., & Giorgi, F. M. (2020) · Genes · doi:10.3390/genes11050556 · Cited by 423
Molecular targeting therapies for neuroblastoma: Progress and challenges
Zafar, A., Wang, W., Liu, G., Wang, X., Xian, W., McKeon, F., Foster, J., Zhou, J., & Zhang, R. (2021) · Medicinal Research Reviews · doi:10.1002/med.21750 · Cited by 380
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119504 · Cited by 345
Metadata
- Authors
- Rettig, I., Koeneke, E., Trippel, F., Mueller, W. C., Burhenne, J., Kopp-Schneider, A., Fabian, J., Schober, A., Fernekorn, U., von Deimling, A., Deubzer, H. E., Milde, T., Witt, O., & Oehme, I.
- Venue
- Cell Death & Disease
- Published
- 2015-02-19
- Volume
- 6
- Issue
- 2
- Pages
- e1657-e1657
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2020769038
- Cited by
- 180
- References
- 12
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. https://app.cochat.ai/papers/10.1038/cddis.2015.24
- The paper
- Rettig, I., Koeneke, E., Trippel, F., Mueller, W. C., Burhenne, J., Kopp-Schneider, A., Fabian, J., Schober, A., Fernekorn, U., von Deimling, A., Deubzer, H. E., Milde, T., Witt, O., & Oehme, I. (2015). Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. Cell Death & Disease. https://doi.org/10.1038/cddis.2015.24
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.